$0.100
-0.025 (-24.98%)收盘时
- High
- 0.131
- Open
- 0.126
- VWAP
- 0.10
- Vol
- 4.48M
- Mkt Cap
- 21.86M
- Low
- 0.081
- Amount
- 465.44K
- EV/EBITDA, TTM
- 0.00
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers.
估值指标
事件时间线
资讯
7.512-22GlobenewswireVince Trust Launches Christmas Rewards Program Offering Up to $10,000 in Incentives
7.512-19GlobenewswireVince Trust Launches Christmas User Incentive Program Offering Up to $6,400 in Rewards
4.504-21BenzingaUS Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert
9.004-17NewsfilterVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
9.004-17Business InsiderVincerx Pharma announces plan to delist from Nasdaq
VINC FAQ — answered by Alphio AI
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。